Oxaliplatin Kabi

Oxaliplatin, the active ingredient in Oxaliplatin Kabi, is a platinum-based chemotherapy presented as a sterile solution for intravenous infusion use. It treats colorectal cancer and other gastrointestinal malignancies in adult patients. GNH USA supplies Oxaliplatin Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

GNH USA supplies Oxaliplatin Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Oxaliplatin Kabi is a platinum‑based chemotherapeutic agent used in the treatment of cancers that arise from the gastrointestinal tract.

- Colorectal cancer: enhances the efficacy of combination regimens, improving survival outcomes. - Gastric cancer: used in combination with fluoropyrimidines to increase response rates. - Pancreatic cancer: added to multi‑drug protocols to augment tumor control. - Esophageal cancer: contributes to disease control when incorporated in neoadjuvant protocols. - Metastatic colorectal cancer : provides a therapeutic option for disease that has progressed beyond first‑line therapy. - C‑     

Oxalipliate ​  

t